Tolerability of Bisoprolol on Domiciliary Spirometry in COPD

Lipworth B, Skinner D, Devereux G, Thomas V, Ling Zhi Jie J, Martin J et al (2016) Underuse of beta-blockers in heart failure and chronic obstructive pulmonary disease. Heart 102(23):1909–1914

Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E (2005) Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 98(7):493–497

Salpeter S, Ormiston T, Salpeter E (2005) Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 19(4):Cd003566

Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes–characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg’s Arch Pharmacol 369(2):151–159

Lipworth BJ, Irvine NA, McDevitt DG (1991) A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol 40(2):135–139

Jabbal S, Anderson W, Short P, Morrison A, Manoharan A, Lipworth BJ (2017) Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. QJM. doi: 10.1093/qjmed/hcx155

Swanney MP, Jensen RL, Crichton DA, Beckert LE, Cardno LA, Crapo RO (2000) FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med 162(3 Pt 1):917–919

Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA (2014) Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 189(3):250–255

Jensen MT, Marott JL, Lange P, Vestbo J, Schnohr P, Nielsen OW et al (2013) Resting heart rate is a predictor of mortality in COPD. Eur Respir J 42(2):341–349

Baker JG (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 144(3):317–322

Lipworth BJ, Brown RA, McDevitt DG (1989) Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. Br J Clin Pharmacol 28(1):95–102